Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers

Manisit Das and Leaf Huang
Division of Pharmacoengineering and Molecular Pharmaceutics, and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Received October 31, 2018; accepted December 11, 2018

ABSTRACT
Gastrointestinal (GI) cancers like liver, pancreatic, colorectal, and gastric cancer remain some of the most difficult and aggressive cancers. Nanoparticles like liposomes had been approved in the clinic for cancer therapy dating as far back as 1995. Over the years, liposomal formulations have come a long way, facing several roadblocks and failures, and advancing by optimizing formulations and incorporating novel design approaches to navigate therapeutic delivery challenges. The first liposomal formulation for a GI cancer drug was approved recently in 2015, setting the stage for further clinical developments of liposome-based delivery systems for therapies against GI malignancies. This article reviews the design considerations and strategies that can be used to deliver drugs to GI tumors, the wide range of therapeutic agents that have been explored in preclinical as well as clinical studies, and the current therapies that are being investigated in the clinic against GI malignancies.

Introduction
Gastrointestinal (GI) cancers are one of the major contributors to cancer-related mortalities worldwide. Colorectal and pancreatic cancers are ranked at third and fourth in the list of top 10 cancers by death rates among both males and females, and cancers of the liver and intrahepatic bile duct rank at fifth and eighth in men and women in the list of estimated deaths, respectively, in the United States (Siegel et al., 2018). Chemotherapy is one of the primary treatment modalities used to treat cancer, along with radiation therapy and surgery. However, drug delivery in diseases localized in the GI tract is challenged by the requirements of low systemic distribution and maximizing therapeutic concentrations along the tract. Further, the GI tract can present an extreme environment for therapeutic delivery with factors like pH, immune response, intestinal permeability, and mucosal barriers posing hurdles (Ensigh et al., 2012). Additionally, solid tumors in themselves can impose intricate barriers in the altered tumor microenvironment and aberrant vasculatures (Sriraman et al., 2014). Together, these challenges in drug delivery require therapeutic delivery in high doses, which contributes to systemic toxicity and drug resistance.

Liposomal structures are spherical vesicles with a lipid layer encapsulating an aqueous core and were described as early as 1965 (Bangham et al., 1965). Since then, liposomes were explored widely as a delivery platform for gene therapies, biologic agents, and chemotherapeutic drugs, leading to the earliest clinical approvals of liposomal drug formulations against cancer with Doxil (1995) and DaunoXome (1996) 3 decades after the discovery of liposomes (Sercombe et al., 2015; Bulbake et al., 2017). Onivyde, a liposomal irinotecan formulation (Fig. 1) was recently approved for use in patients with metastatic pancreatic cancer resistant to gemcitabine (Kipps et al., 2017). Currently, liposomal irinotecan is being explored clinically against multiple GI cancer types including colorectal, gastrointestinal, and biliary cancers (Table 1).

This work is supported by the National Institutes of Health [Grant CA198999]. L.H. is a cofounder of OncoTrap, Inc. No other potential conflicts of interest relevant to this article are reported.

ABBREVIATIONS: BSB, binding site barrier; EphA2, ephrin receptor A2; EPR, enhanced permeation and retention; GI, gastrointestinal; LCP, lipid calcium phosphate; miRNA, microRNA; MPS, mononuclear phagocyte system; PEG, polyethylene glycol; RFA, radiofrequency ablation; siRNA, short interfering RNA.
Herein, we concisely review the liposomal technologies used to deliver therapies against GI cancers and the formulation strategies applied to circumvent the barriers of drug delivery to GI and solid tumors.

Design Considerations in Anticancer Therapy

GI cancers offer challenging barriers for drug delivery by combining the hurdles associated with solid tumors, the GI tract physiologic environment, and the tight epithelial tissue barriers if systemic delivery is required (Tscheik et al., 2013). Liposomal compositions need to be tuned to the intended therapeutic challenge and route of administration. However, some general guidelines can be used for designing the nanoplatforms. For in vivo delivery of nanoparticles, several factors must be taken into consideration, like colloidal stability, interaction with proteins in the serum, shelf life, blood circulation time, mononuclear phagocyte system (MPS) clearance, tissue extravasation, and cytokine induction (Cheng and Lee, 2016). Advancements in the pharmacokinetic properties of liposomal formulations, and enhancement of cargo encapsulation using active loading principles were two key events in liposomal design that eventually led to the clinical approval of Doxil, PEGylated liposomal doxorubicin, in 1995 (James et al., 1994; Harrison et al., 1995; Northfelt et al., 1997). Steric stabilization of liposomes by incorporation of PEGylated phospholipids significantly increased blood circulation time (Blume and Cevc, 1990; Kilbanov et al., 1990), which further enabled passive accumulation in organs with leaky vasculature, by virtue of the “enhanced permeation and retention” (EPR) effect (Matsumura and Maeda, 1986; Torchilin, 2011; Maeda et al., 2016). Further, active loading principles, exploiting the pH gradient between the interior and exterior of the liposome, allowed higher drug encapsulation and minimized nonencapsulated drug loss (Mayer et al., 1986; Bally et al., 1988). Currently, the active loading of liposomes continues to remain a clinically relevant approach for weakly basic drugs and can be exchanged through the liposomal membrane when subjected to a pH gradient. The recently approved Onivyde (2015), a liposomal formulation of irinotecan for patients with metastatic pancreatic adenocarcinoma who are resistant to gemcitabine, exploits multivalent anionic polymeric/nonpolymeric trapping agents like sucrose octasulfate (Fig. 1) providing an electrochemical gradient to facilitate drug retention in the interior of liposomes (Drummond et al., 2006; Passero et al., 2016; Drummond et al., 2018). In this section, we will review the different strategies that can be exploited to design formulations for drug delivery in GI cancers.

Oral Delivery of Formulations. Oral delivery is usually a preferred route for gastroenterological conditions; however, with metastatic cancers, the systemic delivery of therapeutic agents is ideal to enhance drug distribution. Moreover, oral delivery using platforms like liposomal nanoparticles may suffer from instability and degradation of the carrier in the GI tract, mediated by gastric acids, lipases secreted from the pancreas, bile salts (Hu et al., 2013a; He et al., 2018), and scalability. Higher drug doses are usually required for oral formulations, requiring scaling up of liposomes, leading to interbatch variability (He et al., 2018). If permeation across intestinal epithelia is desired, it can be a further challenge. Constant renewal of the dynamic GI mucus barrier can restrict intestinal absorption of nanoparticle systems like liposomes (Ensign et al., 2012). Mucoadhesive and mucopenetrating polymers can be used to modify liposomes to enhance intestinal delivery of therapeutic agents (Liu et al., 2018). Alteration in the composition of gut microbiome may also affect...
drug delivery by impacting intestinal and colonic transit time, mucus production, and immune cell infiltration (Mittal et al., 2018). There had been efforts to exploit cells lining the epithelium, like M cells, to facilitate the transport of liposomal nanoparticles (Shukla et al., 2016). For localized cancers, therapeutic release in a site-specific manner is ideal when surgical resection is not an option. For malignancies of the lower GI tract like cancers of the colon and rectum (Gulbake et al., 2016), factors like temporal control, pH, the enzymatic environment, and pressure can be used to actuate drug release in a specific section of the GI tract as the formulation passes through the gut. So far, there has been limited success in enhancing oral formulations targeting disease using nanomedicine as a drug delivery system (Jain and Stylianopoulos, 2010; Bae and Park, 2011; Harrington et al., 2001). Further, in some human malignancies, vascular permeability is not as high as in preclinical models of cancer, and these factors need to be accounted for while selecting patients for treatment using nanomedicine as a drug delivery system (Jain and Stylianopoulos, 2010; Bae and Park, 2011; Lammers et al., 2012). Using labeled PEGylated liposomes to assess the distribution of formulation in the patient’s lesions by noninvasive imaging is an insightful approach to predict the utility of passive drug targeting while recruiting patients for therapy in the clinic (Harrington et al., 2001).

**Enhanced Permeation and Retention Effect.** Nanoparticle-based platforms can accumulate preferentially in tumors taking advantage of the EPR effect (Matsumura and Maeda, 1986). Previous studies demonstrated increased accumulation of nanoparticle systems within the tumor, compared with normal tissues corresponding to the same organ, in several of the GI malignancies like pancreatic adenocarcinoma, colorectal cancer, and stomach cancer (Natfji et al., 2017). Nanoparticles, because of their size, can preferentially accumulate in tumors, liver, and spleen due to leaky endothelial barriers of these tissues (Li and Huang, 2008). Further, it is possible to tune the size of the nanoparticles to enhance blood circulation time (Liu et al., 1992) and to minimize clearance because of internalization by the cells of the MPS. Surface modification of the liposomal carriers with PEG, commonly referred to as PEGylated liposomes, may reduce opsonization after interaction with components in the blood and subsequent uptake by MPS (Deshpande et al., 2013). Improving blood circulation time and reduction in opsonization can further increase EPR-mediated uptake as it allows the formulation to circulate through the intended site of drug delivery (Torchilin, 2007). Nanoparticle size plays a critical role in guiding uptake in the solid tumor, and the magnitude of the difference in accumulation between smaller and larger liposomes increases with larger tumors as they tend to be more vascularized (Fanciullino et al., 2014). However, it must be noted that, clinically, there is a high degree of interpatient and intrapatient heterogeneity when it comes to EPR effect in human tumors (Maeda, 2015; Clark et al., 2016). Further, in some human malignancies, vascular permeability is not as high as in preclinical models of cancer, and these factors need to be accounted for while selecting patients for treatment using nanomedicine as a drug delivery system (Jain and Stylianopoulos, 2010; Bae and Park, 2011; Lammers et al., 2012). Using labeled PEGylated liposomes to assess the distribution of formulation in the patient’s lesions by noninvasive imaging is an insightful approach to predict the utility of passive drug targeting while recruiting patients for therapy in the clinic (Harrington et al., 2001).

**PEGylated Liposomes: Issues with Anti-PEG Immunity.** Although the PEGylation of liposomes is a commonly used stealth strategy, recent reports (Yang and Lai, 2015; Zhang et al., 2016b) demonstrate that the immune system can induce an antibody response against PEG, resulting in accelerated

### Table 1: Selected liposomal products in clinical development in GI cancers

<table>
<thead>
<tr>
<th>Conditions</th>
<th>Intervention</th>
<th>Phase</th>
<th>Sponsor</th>
<th>Clinical Trials Identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advanced colorectal cancer</td>
<td>CPX-1 (irinotecan HCl: floxuridine)</td>
<td>II</td>
<td>Jazz Pharmaceuticals (Dublin, Republic of Ireland)</td>
<td>NCT00361842</td>
</tr>
<tr>
<td>Gemcitabine-resistant metastatic pancreatic cancer</td>
<td>Liposomal irinotecan (Onivyde)</td>
<td>III (Approved 2015)</td>
<td>Merrimack Pharmaceuticals</td>
<td>NCT01494506</td>
</tr>
<tr>
<td>Gastric, gastroesophageal, and esophageal adenocarcinoma</td>
<td>Oxaliplatin in transferrin-conjugated liposome</td>
<td>I/I</td>
<td>Mebiopharm Co., Ltd. (Tokyo, Japan)</td>
<td>NCT00964080</td>
</tr>
<tr>
<td>Nonresectable hepatocellular carcinoma</td>
<td>ThermoDox (thermally sensitive liposomal doxorubicin)</td>
<td>III</td>
<td>Celsion (Lawrenceville, NJ)</td>
<td>NCT02112656</td>
</tr>
<tr>
<td>Locally advanced/metastatic pancreatic cancer</td>
<td>EndoTAG-1 (paclitaxel in cationic liposomes)</td>
<td>III</td>
<td>SynCore Biotechnology Co., Ltd. (Chang Shan Village, Taiwan)</td>
<td>NCT03126435</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>(LE-DT) docetaxel</td>
<td>II</td>
<td>INSYS Therapeutics Inc. (Phoenix, AZ)</td>
<td>NCT01186731</td>
</tr>
<tr>
<td>Metastatic/unresectable GI cancers</td>
<td>Liposomal irinotecan</td>
<td>I/I</td>
<td>Emory University (Atlanta, GA)</td>
<td>NCT03389963</td>
</tr>
<tr>
<td>Liver cancer</td>
<td>Liposomal doxorubicin with TTFields (alternating electric fields)</td>
<td>I</td>
<td>MD Anderson Cancer Center (Houston, TX)</td>
<td>NCT03203525</td>
</tr>
<tr>
<td>Liver cancer</td>
<td>MTL-CEBPA (CEBPA small activating RNA in liposomes)</td>
<td>I</td>
<td>Mina Alpha Ltd. (London, UK)</td>
<td>NCT02716012</td>
</tr>
<tr>
<td>Metastatic colorectal cancer</td>
<td>SN-38 liposome</td>
<td>II</td>
<td>Alliance for Clinical Trials in Oncology (Boston, MA)</td>
<td>NCT00311610</td>
</tr>
<tr>
<td>Solid tumors including gastric/gastroesophageal/pancreatic ductal adenocarcinoma</td>
<td>(MM-310) docetaxel targeted to antibodies to EphA2 receptor</td>
<td>I</td>
<td>Merrimack Pharmaceuticals</td>
<td>NCT03070372</td>
</tr>
<tr>
<td>Locally advanced/metastatic esophageal carcinoma</td>
<td>PNU-93914 (liposomal paclitaxel)</td>
<td>II</td>
<td>Memorial Sloan-Kettering Cancer Center (New York, NY)</td>
<td>NCT00016900</td>
</tr>
<tr>
<td>Metastatic pancreatic cancer</td>
<td>SGT-53 (human p53 plasmid DNA in cationic liposome)</td>
<td>II</td>
<td>SynerGene Therapeutics, Inc. (Potomac, MD)</td>
<td>NCT02340117</td>
</tr>
<tr>
<td>Primary liver cancer</td>
<td>MRX34 (liposomal miRNA-34a mimic)</td>
<td>I</td>
<td>Mirna Therapeutics, Inc. (Austin, TX)</td>
<td>NCT01829971</td>
</tr>
<tr>
<td>Metastatic pancreatic cancer</td>
<td>Atu027 (liposomal protein kinase N3 siRNA)</td>
<td>I/I</td>
<td>Silence Therapeutics GmbH (Berlin, Germany)</td>
<td>NCT01808638</td>
</tr>
</tbody>
</table>
clearance of PEGylated liposomes and other protein therapeutic agents from the blood. Healthy individuals who are never treated with PEGylated therapeutic agents can have a pre-existing titer of anti-PEG antibodies. A recent report (Chen et al., 2016) showed the presence of either anti-PEG IgG and IgM antibodies in about 44% of patients. Further, pre-existing antibodies against PEG can be a barrier to treat patients with PEG-modified therapeutic agents. A recent phase Ib trial investigating a PEGylated aptamer drug was suspended after three patients were observed to develop a severe allergic reaction against the drug (Povsic et al., 2016). When analyzed retrospectively, these three patients were observed to have elevation in the levels of anti-PEG IgG antibodies, suggesting the association of the pre-existing anti-PEG antibody titer with the potential to induce immune-related adverse events. Currently, alternative stealth polymers like poly(2-oxazoline) are being investigated to shield nanocarriers while bypassing PEG-mediated immune reactions (Bludau et al., 2017).

Active Targeting Approaches. Nanoparticles can be modified with small molecules, peptides, monoclonal antibodies, or antibody fragments to target tumor cells (Fernandes et al., 2015; Jain and Jain, 2018). A wide variety of ligands had been explored in the past to facilitate the tumor-specific uptake of liposomes. Of these surface engineering approaches, some organs are more accessible to target than others. Liposomes and lipid nanoparticles preferentially accumulate in the liver, which can further be tuned with ligand-receptor interactions to shift biodistribution to specific cell populations in the liver like hepatocytes (Longmuir et al., 2009; Goodwin et al., 2016; Huang, 2017). Galactose N-acetylgalactosamine, heparan sulfate, and transferrin are some of the common ligands that have been used in the past to target nanoparticles to the hepatocytes (Li et al., 2009; Hu et al., 2013b). A whole class of functionalized liposomal platforms, the so-called immunoliposomes, have emerged, exploiting antibody or antibody fragments for targeted delivery (Eloy et al., 2017). Monoclonal antibody and antibody fragments targeting CD44 and vascular endothelial growth factor receptor 2 were explored in preclinical models of hepatocellular carcinoma (Roth et al., 2007; Wang et al., 2012). A vascular endothelial growth factor receptor 2–targeted PEGylated formulation of liposomal doxorubicin demonstrated superior efficacy over nontargeted liposomal formulations in murine models of colon cancer (Wicki et al., 2012). Transferrin-conjugated PEG had been used for targeting in preclinical models of gastric cancer as well, demonstrating efficacy over nontargeted liposomes (Inuma et al., 2002). Cationic liposomal platforms targeted with single-chain antibody fragments against the transferrin receptor (Camp et al., 2013) had also been explored in the delivery of wild-type p53, a tumor-suppressor gene, whose mutation can drive oncogenesis in multiple cancers, including cancers of the pancreas (Freed-Pastor and Prives, 2012). Peptides are also exploited to enhance the distribution to tumor cells. Integrin targeting was achieved with tripeptide motifs, enabling specific binding to colon (Schiffelers et al., 2003) and gastric tumors (Akita et al., 2006; Chen et al., 2008), and pentapeptide motifs were used to drive the accumulation of liposomes in angiogenic sites within murine colon tumors (Shimizu et al., 2005). Further, multiple studies exploited immunoliposomes to mitigate the toxicity of chemotherapy drugs and improve efficacy in GI malignancies. Antigen-binding sites of antibodies referred to as Fab’2 fragments were explored for targeting liposomes encapsulating doxorubicin in patients with metastatic or recurring cancers of the stomach (Hosokawa et al., 2004; Matsumura et al., 2004). Liposomes targeting human epidermal growth factor receptor 2 had also been used recently to treat human epidermal growth factor receptor 2–overexpressing gastric cancers (Espelin et al., 2016). Another ErbB receptor family member, epidermal growth factor receptor–targeted oxaliplatin liposomes were also explored in murine colorectal cancer models (Zalba et al., 2015).

Although ligand-decorated nanoparticles were demonstrated to facilitate internalization in targeted cells in numerous preclinical applications, they do not improve biodistribution to tumor tissues, because nanoparticles are distributed predominantly by EPR-guided passive targeting. Hence, nanoparticles having similar blood circulation were observed to have a similar distribution, regardless of active targeting (Goren et al., 1996; Kirpotin et al., 2006; Riviere et al., 2011; Allen and Cullis, 2013). Therefore, recent studies have been focused on understanding binding site barriers (BSBs) to improve the cellular disposition of nanomedicine inside solid tumors (Miao et al., 2016).

The BSB can present itself in many forms. The extracellular matrix and thestromal cells near blood vessels can restrict the diffusion of nanoparticles and further actuate internalization in stromal cells driven by targeting receptor expression. Although these barriers are obstacles to drug delivery, the so-called off-target delivery to fibroblasts can potentially be exploited in anticancer therapy by targeting fibroblasts for therapeutic delivery, inducing the secretion of cytotoxic mediators in the tumor-stroma environment (Miao et al., 2017b). Further, the insights gained from BSB models invite detailed analyses of tumor cell populations to determine receptor expression in distinct cell populations if specific delivery to cancerous cells in the tumor is critical for therapeutic efficacy.

Stimuli-Sensitive Designs. Physiologic triggers like pH, light, enzymes, and redox can be exploited for stimuli-responsive drug delivery by driving structural changes within the liposomal delivery platform, allowing the release of therapeutic cargo in the intended biologic environment (Heidarli et al., 2017; Lee and Thompson, 2017). pH-responsive polymers had been exploited in the past to design liposomes capable of releasing the encapsulated cargo in mildly acidic conditions, like the environment around cancer cells. Copolymer-modified rapamycin liposomes had been investigated as a pH-sensitive delivery platform for colon cancer cells in vitro (Ghanbarzadeh et al., 2014). Multifunctional nanoparticles targeting tumor cells, and using pH sensitivity to release cargo in cancer cells had been designed as well (Garg and Kokkoli, 2011). Overexpression of matrix metalloprotease-9 in the tumor extracellular matrix had been exploited to release encapsulated cargo in the tumor microenvironment driven by matrix metalloprotease-9–mediated lipopeptide cleavage (Kulkarni et al., 2014). Liposomes can be coloaded with superparamagnetic magnetite and a chemotherapeutic agent, and the drug release can be triggered by hyperthermia induced by electromagnetic field (Clares et al., 2013). Thermosensitive liposomes capable of releasing drug cargo triggered by mild hyperthermia were also explored in pancreatic cancer cell lines (Affram et al., 2015). Some of these
stimuli-responsive liposomes had also been tested in the clinic against GI cancers. Recently, the results from a phase III trial investigating radiofrequency ablation (RFA) in combination with heat-sensitive liposomes encapsulating doxorubicin, in patients with hepatocellular carcinoma, were reported (Tak et al., 2018). The study by Tak et al. (2018) did not demonstrate a significant difference in progression-free survival between patients treated with RFA or RFA in combination with thermosensitive doxorubicin liposomes. However, a benefit in patients with solitary lesions was observed. Overall, there are many challenges associated with translating complex nanocarriers to the clinic and with concerns about the cost versus the benefit of targeted nanodelivery systems (Cheng et al., 2012), and these factors need to be taken into consideration for successful clinical translation of multifunctional nanoparticle systems like stimuli-responsive liposomes.

**Combination Therapy by Liposome-Assisted Codeelivery.** Liposomal drug delivery technologies can be exploited to load combination therapeutics in controlled proportions, further tuning the release of drugs from the delivery vehicle, allowing translations of in vitro combination chemotherapeutic synergies to in vivo therapies (Allen and Cullis, 2013; Zununi Vahed et al., 2017). However, coencapsulation of drugs with different physicochemical properties, like solubility and stability, is challenging. Precise control over the loading ratio of drug combinations, which is required for synergistic anticancer therapy, can be difficult to achieve. Nevertheless, distinct classes of drugs like irinotecan with flouxuridine, cytarabine with daunorubicin, cisplatin with daunorubicin, and doxorubicin with salinomycin had been coloaded into liposomes and investigated in murine models of pancreatic and colorectal cancers (Mayer et al., 2006; Sriraman et al., 2015; Gong et al., 2016; Li et al., 2016). Liposomes can also be used to combine different types of payloads, beyond chemotherapeutic agents. Recent studies exploited multiparticled delivery vehicle design approaches, like pH-sensitive cationic liposomes, to load a tyrosine kinase inhibitor drug with short interfering RNAs (siRNA) (Yao et al., 2015) and galactose-targeted liposomes to encapsulate doxorubicin and siRNAs against murine models of liver cancer (Oh et al., 2016). Other nucleic acid therapeutic agents like microRNA (miRNA) can be similarly coloaded in liposomes with chemotherapeutic agents like doxorubicin (Fan et al., 2017). Further, it is possible to design complex systems of hybrid liposomes, encapsulating a drug conjugated to metal nanoparticles, and free drug, allowing an initial rapid release of cargo, and subsequent maintenance of drug level at the target tissue site for prolonged intervals (Zhang et al., 2016a). Another recent study (Wei et al., 2017) exploits thermosensitive liposomes to encapsulate a drug targeting pancreatic stellate cells and human serum albumin nanoparticles of paclitaxel against in vivo models of pancreatic ductal adenocarcinoma. Liposomes are also routinely used in theranostic applications, like coloading gadolinium and kinase inhibitors, for magnetic resonance imaging–guided treatment of hepatocellular carcinoma (Xiao et al., 2016). Biologics like monoclonal antibodies can also be coloaded with photosensitizers to enhance tumor killing mediated by photodynamic therapy and had been investigated in pancreatic cancer models (Tangutoori et al., 2016). There is at least one combination chemotherapy liposomal formulation that had been tested in the clinic against GI malignancies called CPX-1, an equimolar combination of irinotecan HCl with flouxuridine in a phase II trial (NCT00361842) of colorectal cancer. However, the status of the drug combination in clinical development is unknown.

**Payloads and Applications in GI Cancer Therapy**

As we had discussed in the previous segments, liposomes are suited to encapsulate a wide range of therapeutic agents, varying in their physicochemical characteristics and mechanisms of action. Liposomes had been widely investigated in different GI cancers preclinically (Zhang et al., 2013a) and clinically (Table 1) (Cascini et al., 2011; Wang-Gillam et al., 2016; Tak et al., 2018). In this section, we briefly highlight the different therapeutic agents that had been encapsulated using liposomal drug delivery systems for GI malignancies.

**Small Molecules.** Several liposomal formulations of small molecule–based therapeutic agents had been investigated in GI cancers over the years. Targeted and nontargeted liposomal doxorubicin formulations were explored in numerous studies involving preclinical models of colorectal cancer alone (Chang et al., 2010; Falciiani et al., 2011; Lin et al., 2012; Wicki et al., 2012). Other chemotherapeutic agents and small-molecule drugs like antiangiogenic, antifibrotic, and anti-inflammatory agents; photosensitizers; and kinase-targeted therapeutic agents were also routinely investigated (Kan et al., 2011; Mullauer et al., 2011; He et al., 2013; Ranjan et al., 2013; Di Corato et al., 2015; Sriraman et al., 2015). Chemotherapeutic drugs can be modified before encapsulation in liposomal formulations to mitigate cytotoxicity in free tissues and to take advantage of tumor microenvironment–specific factors. PEGylated formulation of a mitomycin C produg was explored in multiple GI tumor models including colon, gastric, and colon cancer, exploiting drug release mediated by reductive factors in tumor tissues (Gabizon et al., 2006, 2012). Alternately, active metabolites of drugs were also formulated to overcome drug resistance mediated by mutational changes within the tumor cells. Gemcitabine triphosphate, a pharmacologically active nucleotide analog and a metabolite of gemcitabine (Zhang et al., 2013b), was formulated in lipid calcium phosphate (LCP) nanoparticles, a nanoformulation with an asymmetric lipid bilayer (Li et al., 2012), and was reported to be efficacious in pancreatic cancer. Tumor-specific factors can further be harnessed to tailor the delivery of small molecules using liposomal formulations in the clinic. Merrimack Pharmaceuticals (Cambridge, MA), who developed Onivyde earlier, is currently investigating (NCT03076372) an ephrin receptor A2 (EphA2) antibody-directed liposomal docetaxel in solid tumors, including gastric and pancreatic cancer. The immunohistochemistry of clinical tumor samples was used to develop a framework for screening patients for inclusion in the clinical trial based on EphA2 expression in the patient’s tumor (Jamou et al., 2016). Overall, these approaches suggest that liposomes have many advantages in mitigating the cytotoxicity of chemotherapeutics and other small molecules, and in augmenting therapeutic benefit by improving drug delivery and release in the tumor. Taking lessons from the early clinical trials, a new generation of liposomal formulations is moving into clinical trials, bringing hope for several GI malignancies with limited therapeutic options.

**Gene Delivery.** Exogenous nucleic acids like DNA, mRNA, siRNA, short hairpin RNA, miRNA, antisense oligonucleotides,
and aptamers have been widely investigated preclinically and clinically for therapy in cancer and other genetic diseases (Ozpolat et al., 2014; Yin et al., 2014; Ramamoorth and Narvekar, 2015; Xiang et al., 2017). Several oligonucleotide therapeutic agents have received regulatory approval over the years (Stein and Castanotto, 2017), including the recent RNA interference drug patisiran, an siRNA formulated in lipid nanoparticles, after a successful phase III clinical trial in patients suffering from hereditary transthyretin amyloidosis (Adams et al., 2018). There are a few studies that have explored liposomes for the delivery of viral vectors in GI cancers (Liu et al., 2011; Wang et al., 2011). The primary objective in those studies was to explore whether liposomes can be exploited to protect adenovirus from neutralizing antibodies. There had been, however, extensive efforts investigating liposomes and other lipid-based products for non-viral gene therapy (Guo and Huang, 2012). The reports of early-phase clinical trials for nucleic acids using liposomes in cancer date as far back as 2004. An antisense oligonucleotide complementary to c-raf-1 proto-oncogene was investigated in 22 patients with advanced solid tumors, and colorectal cancer was the most common cancer type in the patients (Rudin et al., 2004). Although hypersensitivity reactions associated with liposomal formulations hindered the therapeutic administration, this paved the way for preclinical optimization of formulations in subsequent years.

Nucleic acids, in general, are susceptible to degradation by nucleases. Complexation with cationic/ionizable lipids can prevent the degradation of nucleic acids. Further, nucleic acids are required to be delivered into a specific subcellular compartment to achieve its therapeutic function. Liposomes possess the capability to protect nucleic acids along its physiologic journey and mediate cargo release in a specific compartment inside the cells, facilitating cytosolic trafficking and nuclear transport if required (Guo and Huang, 2011; Hu et al., 2013b; Saffari et al., 2016). To mitigate the toxicity of the cationic liposomes without compromising efficacy, extensive efforts were made to design ionizable lipid-based liposomes. The lipid head groups remain unprotonated during circulation; however, they undergo protonation in the acidic pH of the early or late endosome, facilitating interaction with anionic endosomal membrane lipids and promoting cargo release into the cytosol (Kanasty et al., 2013).

A broad range of nucleic acid cargos had been delivered using liposomal formulations in GI cancers (Ozpolat et al., 2014; Harrison et al., 2018). Liposomal formulations of plasmid DNA had been explored in multiple studies with intraperitoneal colon cancers (Kline et al., 2009; Lan et al., 2010; Aoyama et al., 2017). To further increase the stability of the plasmid cargo and achieve improved control over drug release, several polymers like polyethylenimine, poly-L-lysine, and other cationic polymers and polycations had been used to complex with anionic DNA and encapsulate in liposomal nanoparticles (Goodwin and Huang, 2014). Recently, plasmid DNA–based therapeutic agents were explored for nonviral gene therapy and immunotherapy in several GI malignancies including cancers of the colon, pancreas, and liver (Goodwin et al., 2016; Miao et al., 2017a; Shen et al., 2018; Song et al., 2018; Zhou et al., 2018). Plasmid therapy using liposomal formulations had also been explored in patients with advanced solid tumors in a phase I trial, including cancers of the colon and rectum (Senzer et al., 2013). The study demonstrated p53 gene expression in tumors, and the toxicities observed were low grade, leading to a phase II clinical trial in patients with metastatic cancer of the pancreas, which is engaged in ongoing recruiting as of October 2018 (NCT02340117).

Liposomal nanoformulations were also investigated extensively for RNA interference therapies in GI malignancies and other solid tumors (Zhang et al., 2013a; Xin et al., 2017). Atu027, an siRNA against Protein Kinase 3 was encapsulated in liposomes and had been explored in a phase Ib/IIa trial against metastatic pancreatic cancer as a combination therapy with gemcitabine (Aleku et al., 2008; Schultheis et al., 2016). The therapy demonstrated a dose-dependent benefit, and therapy was well tolerated, although grade 3 toxicities were recorded in most patients. Other emerging nucleic acid–based therapeutic agents like miRNA (Shah et al., 2016) had also been explored in the clinic in GI malignancies like liver cancer using liposomal formulations (NCT01829971). Although the expression of target genes was repressed based on patient tumor analyses, the trial had to be suspended because five patients suffered from immune-related adverse events (Peltier et al., 2016; Beg et al., 2017). It is unclear whether the adverse events were mediated by liposomal formulation, alterations in gene expression driven by the miRNA therapeutic agent, or inflammation activated by double-stranded RNA (Dempsey and Bowie, 2015). However, future translational efforts of nucleic acid–based therapeutic agents need to consider these factors to warrant strong antitumor activity while mitigating toxicity associated with the therapeutic agent or its carrier.

Harnessing Liposomal Drug Delivery to Treat Liver Metastases. The liver is a common site of metastasis for a wide variety of primary GI tumors, including colorectal and pancreatic adenocarcinoma (de Ridder et al., 2016). Metastatic dissemination significantly impacts mortality in cancer, accounting for about 90% of cancer-related deaths (Chaffer and Weinberg, 2011). In colorectal cancer patients, 5-year overall survival differs significantly between patients with liver metastases (16.9%) and without liver metastases (70.4%) (Engstrand et al., 2018). Liposomes are well suited for hepatic delivery because of enhanced distribution in the liver, which is further tunable with active targeting. As we discussed previously, several ligands had been used in the past to direct therapeutic agents to hepatocytes.

Recently, LCP nanoparticles with an asymmetric lipid bilayer were shown to be efficacious in delivering plasmids expressing protein traps in murine liver metastasis models of colorectal and breast cancer (Goodwin et al., 2016, 2017). LCP nanoparticles delivering phosphorylated adjuvants and peptides also demonstrated efficacy in arresting colorectal cancer metastasis (Goodwin and Huang, 2017). As discussed earlier, a liposomal formulation of miRNA had also been explored in patients with primary cancers of the liver or liver metastases (Beg et al., 2017). Stimuli triggers were also used preclinically for the treatment of liver metastases. Iron oxide and oxalipatin were loaded in PEGylated liposomes, and drug release was triggered by an alternating magnetic field (Gogineni et al., 2018). In a recently reported phase III trial (Tak et al., 2018), results from a thermosensitive liposomal doxorubicin in combination with RFA in patients with unresectable hepatocellular carcinoma, the treatment of patients with multiple lesions was found to be challenging as repositioning the probe...
for ablation resulted in the loss of local tissue concentration of doxorubicin. Overall, there remain significant challenges associated with drug delivery targeting metastatic tumor sites like the liver warranting increased attention in clinical drug development targeted to metastases over the primary tumor (Ganapathy et al., 2015).

**Liposomal Vaccines.** Liposomes are well suited as vaccine delivery systems in cancer, and beyond. Cationic liposomes and liposomal formulations can augment the immune response to an antigen by stimulation of an innate immune response (Alving et al., 2016). As carrier systems, liposomes can facilitate the antigen uptake, trafficking, processing, and presentation by enhancing lymphatic tissue drainage and tunnelling the release of antigen and adjuvant cargo from the delivery system (Watson et al., 2012; Schwendener, 2014). Several types of macromolecules like DNA, mRNA, peptides, and proteins as antigens can be loaded in liposomes acting as cancer vaccines (Banchereau and Palucka, 2018). Two distinct classes of antigens can be explored as candidates for cancer vaccines, nonmutated tumor antigens, which are overexpressed in cancer tissues with otherwise restricted expression pattern, and neoantigens, which are created by alterations in DNA resulting in the formation of new protein sequences absent from a normal host genome (Schumacher and Schreiber, 2015). Liposomes allow coencapsulation of different classes of adjuvants with antigens in a cancer vaccine, allowing delivery and therapeutic efficacy in highly aggressive and metastatic GI tumor models (Goodwin and Huang, 2017). In the past, liposomal formulations of adjuvants like monophosphoryl lipid A were encapsulated with protein tumor antigens and the vaccine formulations were explored in human patients with colorectal cancer (Neidhart et al., 2004). Further, active targeting principles have been used to target liposomes to immune cell populations like dendritic cells in vivo (Xu et al., 2014; Goodwin et al., 2017), and to bypass the challenges and hurdles of ex vivo antigen priming using donor dendritic cells (Cintolo et al., 2012). Because personalized cancer vaccines are slowly coming of age with peptides and RNA as antigens (Ott et al., 2017; Sabin et al., 2017), we are optimistic about the prospect of liposomal formulations in the development of cancer vaccines in GI malignancies.

**Summary and Perspectives**

Liposomes have come a long way from conceptualization to drug carriers in the clinic, as delivery systems in a wide range of marketed pharmaceutical products. The journey was not a smooth ride, and there were a lot of failures and bumps along the clinical development pathway. Lessons from early clinical trials facilitated optimization of formulations to mitigate toxicities and adverse events. Liposomal formulations are still relevant in cancer drug development, and we witnessed the first clinically approved liposomal formulation for a GI malignancy recently in 2015, using a similar remote loading principle that was exploited to develop Doxil about 20 years ago. Liposomes and other lipid-based nanoparticles have also established their positions as carriers for nucleic acids. Because drug delivery to extrahepatic targets is improved, we can hope to see more gene therapy interventions against GI cancers in the clinic. There are a few therapeutic agents with liposomal formulations that have been actively explored against GI malignancies in human patients. One of these studies (Camp et al., 2013; Senzer et al., 2013) is targeted to restore normal p53 tumor repressor gene function, a protein that is mutated in most patients with pancreatic ductal adenocarcinoma, and is currently being explored in a phase II clinical trial (NCT02340117). Further, nanomedicine drug development is slowly coming of age, as more considerations are applied to recruiting patients. Approaches like analyses of the patient tumor with proportions of cells expressing the protein used for active targeting of liposomes are used to determine whether a specific patient is suitable for treatment with the targeted liposomal drug formulation. This patient selection strategy can also be expanded to take advantage of passive targeting in the right subset of patients. Considering the heterogeneity of EPR, a "one size fits all" approach may not be suitable, and noninvasive imaging should be exploited to determine whether the patient’s tumor is leaky and to be passively targeted by liposomal formulations. In upcoming years, we can expect to see more rationally designed therapeutic agents bypassing the challenges of safety, efficacy, and regulatory hurdles, and making it into the clinic to tackle some of the more challenging GI malignancies, and achieving specific therapeutic objectives.

**Authorship Contributions**

Wrote or contributed to the writing of the manuscript: Das and Huang.

**References**


Das and Huang


Liposomes for Drug Delivery in GI Cancers


Address correspondence to: Dr. Leif Huang, Division of Pharmacoeengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, 301 Pharmacy Lane, 1315 Kerr Hall, CB 7571, Chapel Hill, NC 27599. E-mail: leafl@email.unc.edu